Nateglinide
Back to searchMolecule Structure
Scientific Name
Nateglinide
Description of the Drug
Nateglinide is a meglitinide used to treat non insulin dependent diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00731
http://www.drugbank.ca/drugs/DB00731
Brand Name(s)
Nateglinide, Starlix, Starsis
Company Owner(s)
Alvogen Inc, Watson Laboratories Inc, Dr Reddys Laboratories Ltd, Teva Pharmaceuticals Usa, Novartis Pharmaceuticals Corp, Strides Pharma Global Pte Ltd, Zydus Pharmaceuticals Usa Inc, Cadila Pharmaceuticals Ltd, Rising Pharma Holdings Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sulfonylurea receptor 1, Kir6.2 | PROTEIN COMPLEX | BLOCKER | CHEMBL2096972 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL22088 | |
| DrugBank | DB00731 | |
| PubChem: Thomson Pharma | 14752539 | 14874578 |
| Mcule | MCULE-4748076858 | |
| LINCS | LSM-5555 | |
| Nikkaji | J259.863I | |
| BindingDB | 50344967 | |
| EPA CompTox Dashboard | DTXSID9040687 | |
| DrugCentral | 1886 | |
| ChemicalBook | CB9472923 | |
| Guide to Pharmacology | 6833 | |
| rxnorm | NATEGLINIDE | STARLIX |
| PubChem: Drugs of the Future | 12013966 | |
| ChEBI | 31897 | |
| ZINC | ZINC000101489663 |
